GSK (NYSE:GSK) Sets New 52-Week High – What’s Next?

GSK PLC Sponsored ADR (NYSE:GSK) reached a new 52-week high on Tuesday . The company traded as high as $47.37 and last traded at $47.31, with a volume of 2861642 shares trading hands. The stock had previously closed at $46.63.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GSK. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research note on Monday, October 27th. Weiss Ratings raised GSK from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 31st. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Finally, Cfra set a $53.00 price objective on GSK in a report on Thursday, October 30th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and an average target price of $42.58.

GSK Price Performance

The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $96.17 billion, a price-to-earnings ratio of 13.36, a PEG ratio of 1.90 and a beta of 0.50. The stock has a fifty day moving average of $42.95 and a two-hundred day moving average of $40.21.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. GSK had a return on equity of 51.07% and a net margin of 17.16%.The company had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. During the same period last year, the company posted $0.50 earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be paid a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s dividend payout ratio is 46.05%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Dodge & Cox raised its stake in GSK by 14.9% during the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock worth $3,046,972,000 after buying an additional 10,210,921 shares during the period. Acadian Asset Management LLC increased its holdings in shares of GSK by 201.9% in the first quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock worth $154,244,000 after acquiring an additional 2,663,270 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of GSK during the first quarter worth about $67,267,000. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.4% during the 2nd quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after purchasing an additional 1,306,590 shares in the last quarter. Finally, Clark Capital Management Group Inc. grew its position in shares of GSK by 138.2% in the 1st quarter. Clark Capital Management Group Inc. now owns 1,565,735 shares of the pharmaceutical company’s stock valued at $60,657,000 after purchasing an additional 908,284 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.